29/03/2022
Marie Skłodowska-Curie Actions

MSCA-PF: Joint application at the University of Granada. Department of Physiology.


  • OFFER DEADLINE
    30/09/2022 14:00 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    HE / MSCA
  • LOCATION
    Spain, Granada
  • ORGANISATION/COMPANY
    International Research Projects Office
  • DEPARTMENT
    Promotion and Advisory Unit
  • LABORATORY
    NA

Professor Germaine Escames, from the Department of Physiology at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Postdoctoral Fellowship (MSCA-PF) in 2022 at this University. Please note that applicants must comply with the Mobility Rule (for more information about the 2022 call, please consult: http://sl.ugr.es/0cmA).

Brief description of the institution:

The University of Granada (UGR) was founded in 1531 and is one of the largest and most important universities in Spain. With over 60,000 undergraduate and postgraduate students and 6,000 members of staff, the UGR offers over 70 undergraduate degrees, 100 master’s degrees (9 of which are international double degrees) and 28 doctoral programmes via its 127 departments and 22 centers. Accordingly, the UGR offers one of the most extensive and diverse ranges of higher education programmes in Spain.

The UGR has been awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the institution’s commitment to continuously improving its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The UGR is also internationally renowned for its excellence in diverse research fields and ranked among the top Spanish universities in a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, and international funding.

The UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking - Academic Ranking of World Universities (ARWU). The 2021 edition of the ARWU places the UGR in 201-300th position in the world and as the second highest ranked university in Spain (http://sl.ugr.es/0cmF), reaffirming its position as an institution at the forefront of national and international research. The UGR stands out in the specialties of Library & Information Science (position 36); Food Science & Technology (39) and Hospitality & Tourism Management (51-75), according to the latest edition of this prestigious ranking by specialties (http://sl.ugr.es/0bSp). A little lower in the ranking, the UGR also stands out in Mathematics (76-100) and Mining & Mineral Engineering (76-100).

Additionally, the UGR has 7 researchers who are at the top of the Highly Cited Researchers (HCR) list (http://sl.ugr.es/0cmD), most of these related to the area of Computer Science. It is also well recognized for its web presence (http://sl.ugr.es/0a6i), being positioned at 54th place in the top 200 Universities in Europe.

Internationally, the University of Granada is firmly committed to its participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 67 projects, with total funding of 18.029 million euros, and for H2020, 119 projects with a total funding of around 29.233 million euros.

Brief description of the Centre/Research Group:

I’m Professor at the University of Granada and the Director of the Research Group CTS-101: Intercell Communication. We have been studied the antioxidant effects of melatonin and the identification of the mitochondria as the main target of melatonin. Recently, our activity has focused on studies of the oncostatic activity of melatonin, and on the adverse effects of radio and chemotherapy. We have four international patents on melatonin in the last five years, we have carried out three clinical trials, and one Start Up called Pharmamel. S.L. We are part of the Cost MitoEagle action (EU - OC-2015-2-19984), Member of the CIBER of Fragility and Healthy Aging (CIBERfes) (CB/10/00238) and Member of the Unit of Excellence for the Study of Aging Disorders (UNETE - UCE-PP2017-05). Technical skills and competences in our Group are: Molecular skills (protein, RNA and DNA quantification, protein, RNA and DNAextraction from cells and tissue, PCR, western blots, …); Crispr-cas9 techniques; Mitochondrial respiration analysis (Oroboros and Seahorse); Fluorometric and spectrophotometric techniques; Cytometer skills, HPLC and UPLC; Clock genes rhythms; Cell culture skills (stable cell lines and primary cells culture); mice and zebrafish manipulation; Generation of xenografts and orthograph mice models; Histology, etc. The Group is formed by 28 researches. We have published more than 200 papers; Nº Doctoral Thesis directed in the last 10 years = 29; Google Scholar Total citations =13086; average appointments / year in the last 5 years = 5623; total posts in the first quartile (Q1) = 74; h-index = 64.

Project description:

Our research group has shown that melatonin induces a shift to an aerobic mitochondrial metabolism in tumor cells. Melatonin enhances mitochondrial function and ROS production, reducing the ATP synthesis. The main objective of this project is to determine whether melatonin overcomes multidrug resistance associated with the overexpression of ATP-driven transmembrane efflux pumps and to evaluate new formulations of melatonin, developed by nanobiotechnology, to increase its bioavailability in the tumor. To do this, we will investigate the connections between ABC transporter P-gp, mitochondrial function and cisplatin (CDDP)/paclitaxel resistance. We will use the CDDP/paclitaxel-resistant cells KBChR- 8-5-11, the drug-resistant cells CAL-27 and SCC9 and cells that are genetically modified for the Pgpencoding ABCB1 gene using CRISPR/Cas9 technology. We will evaluate the effects of different melatonin formulations to overcome CDDP and paclitaxel resistance in a mouse xenograft model of drug-resistant head and neck cancer, as well as mouse orthotopic models and patient-derived xenograft models. We will evaluate tumor characteristics by NMR and micro- PET/CT using the routine procedures used with oncological patients and in clinical trials; full mitochondrial function including oxygen consumption, together with other relevant bioenergetic parameters will be measured using Oroboros O2k high-resolution respirometry; P-gp analysis by western blot, PCR of ABCB1 gene, efflux activity of P-gp and drugs levels into cancer cells. Apoptosis, proliferation, differentiation, histology, electronic microscopy, proteomic and metabolomic, among other techniques will be studied in cancer cells; hemogram and biochemical parameters, as well as cytotoxicity in healthy organs, will also be evaluated.

Research Area:

  • Life Sciences (LIFE)

For a correct evaluation of your candidature, please send the documents below to Professor Germaine Escames, (gescames@ugr.es):

  • CV
  • Letter of recommendation (optional)

 

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.